Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

NCT07127822 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

106

Enrollment

OTHER

Sponsor class

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma
MSI-H Cancer

Interventions

DRUG: Iparomlimab and Tuvonralimab
DRUG: First line chemotherapy plus PD-1/PD-L1 antibody

Sponsor

Peking University

Collaborators

[object Object]
[object Object]